Deltex Medical Regulatory News (DEMG)

18 Mar 2005 07:00

Deltex Medical Group PLC18 March 2005 Deltex Medical Group plc Major Order Received from NHS Trust 18 March 2005 - Deltex Medical Group plc ("Deltex Medical" or "Company") todayannounces the receipt of its first major order of 2005 from an NHS Trust toimplement the Company's CardioQTM system as a standard of care in moderate andmajor risk surgery. Birmingham Heartlands and Solihull NHS Trust (Teaching), which runs theBirmingham Heartlands and Solihull hospitals, has placed an order with theCompany for a total of 8 CardioQ monitors to be installed in operating theatresacross the two sites, together with sufficient probes for initial training. TheTrust's internal business case was approved on the basis of it using up to 250probes per month by the end of this first phase of wide-scale implementation ofthe CardioQ. Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amountof circulating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. Andy Hill, Deltex Medical's Chief Executive, said: "Birmingham Heartlands andSolihull are the first UK NHS hospitals to place wide-scale orders for CardioQequipment in 2005. We will be working closely with the hospitals over thecoming months to help them maximise both the clinical and economic benefits ofthe CardioQ. In the meantime, our discussions continue with other NHS trustsregarding implementation of the CardioQ and we expect to announce further ordersas these discussions progress." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, ChairmanAndy Hill, Chief ExecutiveEwan Phillips, Finance Director Financial DynamicsDavid Yates/Lucy Briggs 0207 831 3113 Notes for Editors The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • proved that the CardioQ works in a wide range of surgical procedures • demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock Exchange